Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anixa Biosciences IncANIX · Entity 6698 | Director · Chief Executive Officer | September 24, 2026 | September 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anixa Biosciences Inc
Report date September 24, 2026 · Filed September 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 672,000 |
Reported balance
After 2026-09-24 transaction · row 1
1 source rowRow 1 · 2026-09-24 · Purchase · Acquired 7,000 · Balance 672,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 24, 2026 Filed Sep 28, 2026 12:45 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 7,000 | $2.78 | $19,460.00 |
DisclosureSEC source: 0001493152-26-044458 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 672,000 Read SEC document |
| September 10, 2026 Filed Sep 14, 2026 13:45 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 3,000 | $2.75 | $8,250.00 |
DisclosureSEC source: 0001493152-26-042512 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 665,000 Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 12:00 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 5,000 | $2.76 | $13,800.00 |
DisclosureSEC source: 0001493152-26-042302 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 662,000 Read SEC document |
| July 31, 2026 Filed Aug 3, 2026 08:45 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 5,000 | $3.47 | $17,350.00 |
DisclosureSEC source: 0001493152-26-035751 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 657,000 Read SEC document |
| July 27, 2026 Filed Jul 27, 2026 15:25 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 3,188 | $3.37 | $10,743.56 |
DisclosureSEC source: 0001493152-26-034772 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 647,000 Read SEC document |
| July 27, 2026 Filed Jul 28, 2026 10:20 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 5,000 | $3.44 | $17,200.00 |
DisclosureSEC source: 0001493152-26-034952 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 652,000 Read SEC document |
| July 24, 2026 Filed Jul 27, 2026 09:00 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 3,000 | $3.73 | $11,190.00 |
DisclosureSEC source: 0001493152-26-034723 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 643,812 Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 10:23 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 5,000 | $3.46 | $17,300.00 |
DisclosureSEC source: 0001493152-26-034027 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 640,812 Read SEC document |
| July 10, 2026 Filed Jul 13, 2026 08:59 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 5,000 | $3.04 | $15,200.00 |
DisclosureSEC source: 0001493152-26-032961 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 635,812 Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 09:00 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 21,000 | $2.50 | $52,500.00 |
DisclosureSEC source: 0001493152-26-028827 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 630,812 Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 19:42 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option · Derivative | 350,000 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001493152-26-000688 · ownership.xml · derivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2036-01-05 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable in thirty-six (36) equal monthly installments beginning January 31, 2026. Read SEC document |
| October 30, 2025 Filed Oct 31, 2025 09:13 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001493152-25-020322 · ownership.xml · derivative · entry 3 KUMAR AMIT · CIK 0001191905 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Right-To-Buy, pursuant to a stock option grant dated February 18, 2016. F3 · derivative.exercise_date: The option vested in 36 consecutive monthly installments beginning on March 31, 2016. Read SEC document |
| October 30, 2025 Filed Oct 31, 2025 09:13 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Tax withholdingCommon Stock | 169,439 | $4.06 | $687,922.34 |
DisclosureSEC source: 0001493152-25-020322 · ownership.xml · nonDerivative · entry 2 KUMAR AMIT · CIK 0001191905 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 610,486 F1 · kind: The reporting person exercised the stock options at this time due to their upcoming expiration on February 18, 2026. The disposal of shares reported herein represents shares withheld by Anixa Biosciences, Inc. (the "registrant") to (i) cover the exercise price of the stock options and (ii) satisfy tax withholding obligations in connection with the exercise of the stock options. Dr. Kumar did not sell any shares in connection with the exercise of the options. Read SEC document |
| October 30, 2025 Filed Oct 31, 2025 09:13 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Exercise / conversionCommon Stock | 200,000 | $2.92 | $584,000.00 |
DisclosureSEC source: 0001493152-25-020322 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 779,925 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2025 Filed Jul 31, 2025 09:00 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 5,000 | $3.16 | $15,800.00 |
DisclosureSEC source: 0001641172-25-021679 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 579,925 Read SEC document |
| July 11, 2025 Filed Jul 14, 2025 08:40 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 5,000 | $3.15 | $15,750.00 |
DisclosureSEC source: 0001641172-25-018898 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 574,925 Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 09:11 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 10,000 | $2.85 | $28,500.00 |
DisclosureSEC source: 0001641172-25-013724 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 569,925 Read SEC document |
| January 15, 2025 Filed Jan 15, 2025 13:15 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 43,000 | $2.23 | $95,890.00 |
DisclosureSEC source: 0001493152-25-002321 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 559,925 Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 17:40 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option · Derivative | 700,000 | $0.00 Strike: $2.37 | $0.00 |
DisclosureSEC source: 0001493152-25-000316 · ownership.xml · derivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2035-01-02 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable in thirty-six (36) equal monthly installments beginning January 31, 2025. Read SEC document |
| June 07, 2024 Filed Jun 7, 2024 10:57 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 25,000 | $2.41 | $60,250.00 |
DisclosureSEC source: 0001493152-24-023023 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 516,925 Read SEC document |
| March 15, 2024 Filed Mar 15, 2024 10:49 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 30,000 | $3.22 | $96,600.00 |
DisclosureSEC source: 0001493152-24-010028 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 491,925 Read SEC document |
| January 12, 2024 Filed Jan 16, 2024 19:05 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 700,000 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0001493152-24-002527 · ownership.xml · derivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2034-01-12 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable in thirty-six (36) equal monthly installments beginning January 31, 2024. Read SEC document |
| July 31, 2023 Filed Jul 31, 2023 18:34 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | SaleCommon Stock | 11,800 | $3.57 | $42,126.00 |
DisclosureSEC source: 0001493152-23-026125 · ownership.xml · nonDerivative · entry 3 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 461,925 Read SEC document |
| July 28, 2023 Filed Jul 31, 2023 18:34 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001493152-23-026125 · ownership.xml · derivative · entry 4 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2023-11-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Right-To-Buy, pursuant to a stock option grant dated November 8, 2013. Read SEC document |
| July 28, 2023 Filed Jul 31, 2023 18:34 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Tax withholdingCommon Stock | 28,375 | $3.63 | $103,001.25 |
DisclosureSEC source: 0001493152-23-026125 · ownership.xml · nonDerivative · entry 2 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 473,725 F1 · kind: The reporting persons exercised the stock options at this time due to their expiration on November 8, 2023. The disposal of shares reported herein represents shares withheld by Anixa Biosciences, Inc. (the "registrant") to cover the exercise price of the stock options. Read SEC document |
| July 28, 2023 Filed Jul 31, 2023 18:34 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Exercise / conversionCommon Stock | 40,000 | $2.58 | $103,000.00 |
DisclosureSEC source: 0001493152-23-026125 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 502,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 20:49 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 700,000 | $0.00 Strike: $4.19 | $0.00 |
DisclosureSEC source: 0001493152-23-000417 · ownership.xml · derivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2033-01-03 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable in thirty-six (36) equal monthly installments beginning January 31, 2023. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 17:20 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 640,000 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001493152-22-026121 · ownership.xml · derivative · entry 3 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 640,000 shares Expires 2022-09-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Right-To-Buy, pursuant to a stock option grant dated September 19, 2012. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 17:20 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Tax withholdingCommon Stock | 491,900 | $4.48 | $2,203,712.00 |
DisclosureSEC source: 0001493152-22-026121 · ownership.xml · nonDerivative · entry 2 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 462,100 F1 · kind: The reporting persons exercised the stock options at this time due to their expiration on September 19, 2022. The disposal of shares reported herein represents shares withheld by Anixa Biosciences, Inc. (the "registrant") to (i) cover the exercise price of the stock options and (ii) satisfy tax withholding obligations in connection with the exercise of the stock options. Dr. Kumar did not sell any shares in connection with the exercise of the options. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 17:20 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Exercise / conversionCommon Stock | 640,000 | $2.58 | $1,648,000.00 |
DisclosureSEC source: 0001493152-22-026121 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 954,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 16:15 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001493152-22-006624 · ownership.xml · derivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2032-03-10 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable in thirty-six (36) equal monthly installments beginning March 31, 2022. Read SEC document |
| January 07, 2022 Filed Jan 7, 2022 10:32 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 20,000 | $3.00 | $60,000.00 |
DisclosureSEC source: 0001493152-22-000640 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,000 Read SEC document |
| October 29, 2021 Filed Nov 1, 2021 11:05 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 2,000 | $4.77 | $9,540.00 |
DisclosureSEC source: 0001493152-21-026828 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,000 Read SEC document |
| July 23, 2021 Filed Jul 27, 2021 13:08 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 5,000 | $4.28 | $21,400.00 |
DisclosureSEC source: 0001493152-21-017833 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,000 Read SEC document |
| July 16, 2021 Filed Jul 20, 2021 09:00 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 10,000 | $3.94 | $39,400.00 |
DisclosureSEC source: 0001493152-21-017276 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,000 Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 17:00 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $4.02 | $0.00 |
DisclosureSEC source: 0001493152-21-013453 · ownership.xml · derivative · entry 2 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2031-06-01 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F3 · derivative.exercise_date: The options vest and become exercisable in thirty-six (36) equal monthly installments beginning June 30, 2021. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 17:00 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 2,000,000 | $0.00 Strike: $4.02 | $0.00 |
DisclosureSEC source: 0001493152-21-013453 · ownership.xml · derivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Stock · 2,000,000 shares Expires 2031-06-01 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable as follows: (i) 500,000 shares vest if during any 5 trading day period, the average closing price of the issuer's common stock is at least $5.00, (ii) 500,000 shares vest if during any 5 trading day period, the average closing price of the issuer's common stock is at least $6.00, (iii) 500,000 shares vest if during any 5 trading day period, the average closing price of the issuer's common stock is at least $7.00, and (iv) 500,000 shares vest if during any 5 trading day period, the average closing price of the issuer's common stock is at least $8.00. Read SEC document |
| May 31, 2021 Filed Jun 2, 2021 17:00 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Disposition to issuerRestricted Stock Award · Derivative | 1,500,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-013453 · ownership.xml · derivative · entry 3 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500,000 shares Expires 2021-05-31 F4 · derivative.exercise_date: The vesting requirements were not met and the restricted stock award expired on May 31, 2021. Read SEC document |
| March 25, 2021 Filed Mar 25, 2021 13:43 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 5,000 | $4.86 | $24,300.00 |
DisclosureSEC source: 0001493152-21-006780 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,000 Read SEC document |
| January 29, 2021 Filed Feb 1, 2021 09:00 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 10,000 | $3.73 | $37,300.00 |
DisclosureSEC source: 0001493152-21-002176 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,000 Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 18:10 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,000,000 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0001493152-20-024384 · ownership.xml · derivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2030-12-23 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable in thirty-six (36) equal monthly installments beginning December 31, 2020. Read SEC document |
| September 11, 2020 Filed Sep 11, 2020 11:58 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 28,000 | $2.11 | $59,080.00 |
DisclosureSEC source: 0001493152-20-017605 · ownership.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,000 Read SEC document |
| June 12, 2020 Filed Jun 12, 2020 10:48 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 20,000 | $2.03 | $40,600.00 |
DisclosureSEC source: 0001513162-20-000123 · primary_doc.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,000 Read SEC document |
| March 12, 2020 Filed Mar 12, 2020 10:26 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 20,000 | $1.82 | $36,400.00 |
DisclosureSEC source: 0001513162-20-000047 · primary_doc.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,000 Read SEC document |
| January 14, 2020 Filed Jan 14, 2020 10:47 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 20,000 | $2.99 | $59,800.00 |
DisclosureSEC source: 0001513162-20-000015 · primary_doc.xml · nonDerivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,000 Read SEC document |
| December 12, 2019 Filed Dec 16, 2019 17:14 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 520,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001513162-19-000250 · primary_doc.xml · derivative · entry 1 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 520,000 Underlying: Common Stock · 520,000 shares Expires 2019-12-12 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable in thirty-six (36) equal monthly installments beginning December 31, 2019. Read SEC document |
| September 20, 2019 Filed Sep 20, 2019 17:37 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option · Derivative | 200,000 | Not disclosed Strike: $2.92 | Not disclosed |
DisclosureSEC source: 0001513162-19-000212 · primary_doc.xml · derivative · entry 10 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2026-02-18 F1 · kind: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F5 · derivative.exercise_date: The option was originally granted on February 18, 2016 and vested in 36 consecutive monthly installments beginning on March 31, 2016. Read SEC document |
| September 20, 2019 Filed Sep 20, 2019 17:37 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Disposition to issuerEmployee Stock Option · Derivative | 200,000 | Not disclosed Strike: $0.67 | Not disclosed |
DisclosureSEC source: 0001513162-19-000212 · primary_doc.xml · derivative · entry 9 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2026-02-18 F1 · kind: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F5 · derivative.exercise_date: The option was originally granted on February 18, 2016 and vested in 36 consecutive monthly installments beginning on March 31, 2016. Read SEC document |
| September 20, 2019 Filed Sep 20, 2019 17:37 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option · Derivative | 40,000 | Not disclosed Strike: $2.58 | Not disclosed |
DisclosureSEC source: 0001513162-19-000212 · primary_doc.xml · derivative · entry 8 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2023-11-08 F1 · kind: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F4 · derivative.exercise_date: The option was originally granted on November 8, 2013 and vested in 36 consecutive monthly installments beginning on December 31, 2013. Read SEC document |
| September 20, 2019 Filed Sep 20, 2019 17:37 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Disposition to issuerEmployee Stock Option · Derivative | 40,000 | Not disclosed Strike: $0.67 | Not disclosed |
DisclosureSEC source: 0001513162-19-000212 · primary_doc.xml · derivative · entry 7 KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2023-11-08 F1 · kind: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F4 · derivative.exercise_date: The option was originally granted on November 8, 2013 and vested in 36 consecutive monthly installments beginning on December 31, 2013. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.